Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Using Mass-Spectrometry-Based Cancer Proteomics Datasets to Discover Potential Therapeutic Targets

A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, "Using cancer proteomics data to identify gene candidates for therapeutic targeting."

11 May 2023

Cancer Stem Cell Test can Accurately Decide More Effective Treatments for Glioblastoma Patients

New multi-institutional phase 3 clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma, a deadly brain tumor.

8 May 2023

Study Reveals an Immunological Strategy to Overcome Microbiome-Related Immunotherapy Resistance

Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.

4 May 2023

Mini Organs Provide New Insights Into Fibrolamellar Carcinoma

Scientists of the Princess Máxima Center for pediatric oncology and Hubrecht Institute in the Netherlands have revealed new scientific insights into the features of fibrolamellar carcinoma (FLC), a rare type of childhood liver cancer

4 May 2023

New Bio-Inspired Molecules can Enhance Bone Regeneration in Mice

People's ability to regenerate bones declines with age and is further decreased by diseases such as osteoporosis.

2 May 2023

New Genetic Mutations Linked to Canine Bladder Cancers Identified

Researchers have identified new genetic mutations linked to a subset of canine bladder cancers. Their findings have implications both for early cancer detection and for targeted treatments in dogs and humans.

26 Apr 2023

Blocking Necroptosis Could Lead to the Inhibition of Cancer Metastasis

A new editorial paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, "Tumor necroptosis promotes metastasis through modulating the interplay between tumor and host immunity."

25 Apr 2023

Study Uncovers a Protein-Protein Interaction Related to Parkinson's Disease

In a study published in Nature Communications, a team led by Krembil Brain Institute Senior Scientists, Drs. Lorraine Kalia and Suneil Kalia, and University of Toronto (U of T) Professor, Dr. Philip M. Kim, identified a protein-protein interaction that contributes to Parkinson's disease.

24 Apr 2023

Increased Fucose Digestion by Gut Bacteria Linked to Lower Immune Responses to COVID-19 Vaccine

Gut bacteria that break down a sugar called fucose could be dampening our immune response to the COVID-19 mRNA vaccine, according to a study led by researchers from the Okinawa Institute of Science and Technology.

21 Apr 2023

Deletion of Specific Protein Creates a Hostile Environment for Aggressive Breast Tumors

Scientists at VCU Massey Cancer Center discovered that the deletion of a specific protein creates a hostile environment for tumor cells and significantly subdues breast cancer growth and spread.

13 Apr 2023

New Method for Improving Gene Therapy With Nanobubbles

Beyond vaccines, mRNA offers immense potential to fight disease, but targeting the genetic material to specific diseased cells is challenging-; requiring a new method.

12 Apr 2023

Immunotherapy Response in Advanced Melanoma: Effect of Previous Treatments

According to a study conducted by UCLA, patients with advanced melanoma responded differently to PD-1 checkpoint blockade immunotherapy depending on a variety of variables, including whether or not they had previously received CTLA-4 blockade, another type of immunotherapy.

11 Apr 2023

Gut Microbiome and Enhanced Tumor Immune Response in Pancreatic Cancer Survivors

Even as pancreatic cancer treatments advance, only around 9% of patients live beyond five years. Scientists have failed to identify genetic distinctions that explain why some patients live for a long time and others do not, so they have moved their emphasis to the gut microbiome.

5 Apr 2023

Insights into mechanisms impacting NSCLC disease progression

Proteomics is the study and analysis of proteins in a biological system, including their structures, functions, associations, and alterations.

5 Apr 2023

Previously unknown telomere and cancer connection to the immune system revealed

Johns Hopkins Medicine scientists say their 20-year study of more than 200 people with premature aging syndromes caused by abnormally short telomeres, or shortened repetitive DNA sequences at the ends of chromosomes, may upend long-held scientific dogma and settle conflicting studies about how and whether short telomeres contribute to cancer risk.

31 Mar 2023

Neutrophils can affect the success of immunotherapy in treating cancer, study shows

Cancer immunotherapies that recruit a patient's own immune system to destroy tumors have transformed the treatment of many types of cancer. Yet these therapies do not elicit universally good treatment responses.

31 Mar 2023

Inaugural college and career program for oncology, hematology patients helps 'unlock' their future

On Thursday, March 2, 42 teens and young adults, all patients in the Adolescent and Young Adult Oncology Program (AYA), attended “Unlock Your Future,” the inaugural college and career program for oncology and hematology patients.

21 Mar 2023

New combination therapy regimen may reduce prostate cancer progression or death by 37%

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

20 Mar 2023

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).